These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 726743)
1. [Chemical and immunogenic properties of the capsular antigen of Staphylococcus aureus. III. Protective activity of capsular antigen in experiments on mice]. Akatov AK; Prokhorov VIa; Witte W; Kühn M; Seltmann G Zh Mikrobiol Epidemiol Immunobiol; 1978 Nov; (11):47-52. PubMed ID: 726743 [TBL] [Abstract][Full Text] [Related]
2. Preclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection. Li X; Wang X; Thompson CD; Park S; Park WB; Lee JC mBio; 2016 Feb; 7(1):e02232-15. PubMed ID: 26838725 [TBL] [Abstract][Full Text] [Related]
4. Targeting the R domain of coagulase by active vaccination protects mice against lethal Staphylococcus aureus infection. Qian M; Zhao T; Li R; Yang Q; Yu R; Yin Y; Zai X; Li Y; Zhang J; Xu J; Chen W Microbes Infect; 2019; 21(3-4):163-169. PubMed ID: 30447395 [TBL] [Abstract][Full Text] [Related]
6. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. Lattar SM; Noto Llana M; Denoël P; Germain S; Buzzola FR; Lee JC; Sordelli DO Infect Immun; 2014 Jan; 82(1):83-91. PubMed ID: 24126523 [TBL] [Abstract][Full Text] [Related]
7. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Schaffer AC; Solinga RM; Cocchiaro J; Portoles M; Kiser KB; Risley A; Randall SM; Valtulina V; Speziale P; Walsh E; Foster T; Lee JC Infect Immun; 2006 Apr; 74(4):2145-53. PubMed ID: 16552044 [TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of vaccine against Staphylococcus aureus recovered from naturally occurring mastitis in she-camels. Aqib AI; Anjum AA; Ijaz M; Hussain R; Ahmed R; Farooqi SH; Aslam HB; Hussain K; Mehmood K; Zhang H Microb Pathog; 2018 Apr; 117():341-347. PubMed ID: 29510207 [TBL] [Abstract][Full Text] [Related]
9. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Nissen M; Marshall H; Richmond P; Shakib S; Jiang Q; Cooper D; Rill D; Baber J; Eiden J; Gruber W; Jansen KU; Emini EA; Anderson AS; Zito ET; Girgenti D Vaccine; 2015 Apr; 33(15):1846-54. PubMed ID: 25707693 [TBL] [Abstract][Full Text] [Related]
10. S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine. Marshall HS; Baber J; Richmond P; Nissen M; Shakib S; Kreiswirth BN; Zito ET; Severs J; Eiden J; Gruber W; Jansen KU; Jones CH; Anderson AS J Infect; 2019 Dec; 79(6):582-592. PubMed ID: 31585191 [TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. Frenck RW; Creech CB; Sheldon EA; Seiden DJ; Kankam MK; Baber J; Zito E; Hubler R; Eiden J; Severs JM; Sebastian S; Nanra J; Jansen KU; Gruber WC; Anderson AS; Girgenti D Vaccine; 2017 Jan; 35(2):375-384. PubMed ID: 27916408 [TBL] [Abstract][Full Text] [Related]
12. Induction of resistance in mice by the capsular polysaccharide antigens of Staphylococcus aureus. Yoshida K; Umeda A; Ohshima Y Microbiol Immunol; 1987; 31(7):649-56. PubMed ID: 3125414 [TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial. Creech CB; Frenck RW; Sheldon EA; Seiden DJ; Kankam MK; Zito ET; Girgenti D; Severs JM; Immermann FW; McNeil LK; Cooper D; Jansen KU; Gruber W; Eiden J; Anderson AS; Baber J Vaccine; 2017 Jan; 35(2):385-394. PubMed ID: 27866765 [TBL] [Abstract][Full Text] [Related]
14. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. Hu DL; Narita K; Hyodo M; Hayakawa Y; Nakane A; Karaolis DK Vaccine; 2009 Jul; 27(35):4867-73. PubMed ID: 19406185 [TBL] [Abstract][Full Text] [Related]
15. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study. Fattom A; Matalon A; Buerkert J; Taylor K; Damaso S; Boutriau D Hum Vaccin Immunother; 2015; 11(3):632-41. PubMed ID: 25483694 [TBL] [Abstract][Full Text] [Related]
16. The World Needs a Staph Vaccine-New Research Could Bring It a Step Closer. Coffey D JAMA; 2024 Aug; 332(8):607-609. PubMed ID: 39093572 [TBL] [Abstract][Full Text] [Related]
18. Active immunization with an octa-valent Staphylococcus aureus antigen mixture in models of S. aureus bacteremia and skin infection in mice. van den Berg S; Koedijk DG; Back JW; Neef J; Dreisbach A; van Dijl JM; Bakker-Woudenberg IA; Buist G PLoS One; 2015; 10(2):e0116847. PubMed ID: 25710376 [TBL] [Abstract][Full Text] [Related]
19. Staphylococcus aureus antigens and challenges in vaccine development. Middleton JR Expert Rev Vaccines; 2008 Aug; 7(6):805-15. PubMed ID: 18665778 [TBL] [Abstract][Full Text] [Related]
20. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Begier E; Seiden DJ; Patton M; Zito E; Severs J; Cooper D; Eiden J; Gruber WC; Jansen KU; Anderson AS; Gurtman A Vaccine; 2017 Feb; 35(8):1132-1139. PubMed ID: 28143674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]